Skip to main content
. 2018 Mar 7;9:335. doi: 10.3389/fimmu.2018.00335

Table 5.

Seroprevalence of AdHu5 and AdC68 neutralizing antibodies in subjects with different clinical stage of cancer.

Clinical stage AdHu5 AdC68 P-value
Stage I 61.65% (82/133) 41.35% (55/133) 0.001
Stage II 66.67% (108/162) 43.83% (71/162) 0.000
Stage III 72.17% (83/115) 44.35% (51/115) 0.000
Stage IV 73.33% (22/30) 50.00% (15/30) 0.063